title: Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis: a pharmacokinetic study.
authors.affiliation: aDepartment of Medicine and Clinical Science bDepartment of Clinical Pharmacology, Gunma University Graduate School of Medicine cJomo Ohashi Clinic dSaruki Clinic, Maebashi, Gunma, Japan.
authors.forename: Kunio
authors.initials: K
authors.lastname: Yanagisawa
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nagano
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Hideki
authors.initials: H
authors.lastname: Uchiumi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Shigehara
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Saruki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
authors.forename: Takuya
authors.initials: T
authors.lastname: Araki
authors.forename: Koujirou
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nojima
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068898:Raltegravir Potassium / Q000008:administration & dosage* / Q000009:adverse effects*; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D000068898:Raltegravir Potassium